SCHEMBL3222871

SCHEMBL3222871

C=CCNc1ccc(C(F)(F)F)cc1I

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TGM2 P21980 1/20 0.35
RECQL P46063 1/20 0.34
LIPC P11150 1/20 0.34
LIPG Q9Y5X9 1/20 0.34
HCAR3 P49019 1/20 0.34
MEN1 O00255 3/20 0.33
ALDH1A1 P00352 3/20 0.33
KMT2A Q03164 3/20 0.33
GAA P10253 2/20 0.33
MAPT P10636 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GFER P55789 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PKM P14618 1/20 0.33
KRAS P01116 1/20 0.31
ALPL P05186 1/20 0.31
ALPI P09923 1/20 0.31
CA12 O43570 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3889836 0.76 LIPC (0.61) LIPCLIPGHCAR3ALDH1A1KDM4E
SCHEMBL7130826 0.75 HCAR3 (0.60) LMNASMN1; SMN2HCAR3MEN1ALDH1A1
SCHEMBL27668346 0.73 ALDH1A1 (0.40) LIPCLIPGMEN1ALDH1A1KMT2A
SCHEMBL18299485 0.73 RAPGEF4 (0.38) LMNASMN1; SMN2ALDH1A1ALPLALPI
SCHEMBL31497276 0.72 TGM2 (0.53) LMNASMN1; SMN2TGM2MEN1ALDH1A1
SCHEMBL4050847 0.72 ALDH1A1 (0.42) LMNASMN1; SMN2TGM2LIPCLIPG
SCHEMBL15955512 0.72 ALDH1A1 (0.42) SMN1; SMN2MEN1ALDH1A1KMT2AGAA
SCHEMBL29643387 0.71 RXFP1 (0.43) LIPCLIPGMEN1ALDH1A1KMT2A
SCHEMBL21885675 0.71 RXFP1 (0.43) LIPCLIPGMEN1ALDH1A1KMT2A
SCHEMBL30406158 0.70 MAPT (0.49) LMNASMN1; SMN2RECQLMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142516-B1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI SA (FR) 2012-12-26 EP disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 LMNA 3470/4885SMN1; SMN2 4832/4885TGM2 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.